Good news for our French customers! We have renewed our French CIR tax accreditation for 2016-2018. So you will continue to benefit from 20-30% tax relief when you use our services.
“The renewal of the CIR accreditation for an additional three-year period will provide additional tangible benefits to our customers in France, who can rely on Aptuit for their integrated drug discovery and development needs", Aptuit CEO Jonathan Goldman commented. "Our expertise and capabilities have been enhanced recently by the addition of specialist drug pre-formulation, formulation prototyping and formulation development services through our acquisition of Kuecept in UK, and with our acquisition of Exquiron in Switzerland for High Throughput Screening and other early discovery services".